2 completed, 2 terminated, 1 recruiting. 5 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 2, Terminated 2, Recruiting 1 |
Follow sovateltide: new trials by email Literature Review of sovateltide trials Research Report on sovateltide
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PMZ-1620 (Sovateltide) in Patients of Acute Spinal Cord Injury Normal Saline along with standard treatment, PMZ-1620 along with standard treatment - Acute Spinal Cord Injury | Phase 2 | Recruiting | Pharmazz, Inc. | 40 | 2019-01-10 | 2025-07-04 |
| PMZ-1620 (Sovateltide) in Mild to Moderate Alzheimer's Disease Normal Saline along with standard treatment, PMZ-1620 (sovateltide) along with standard treatment - Alzheimer Disease, Dementia | Phase 2 | Completed | Pharmazz, Inc. | 80 | 2018-03-23 | 2023-01-12 |
| PMZ-1620 (Sovateltide) in Acute Ischemic Stroke Patients Normal Saline along with standard treatment, PMZ-1620 along with standard treatment - Acute Stroke, Cerebral Ischemia | Phase 2 | Completed | Pharmazz, Inc. | 40 | 2018-01-19 | 2025-05-12 |
| Study of SPI-1620 in Combination With Docetaxel Versus Docetaxel Alone for Patients With Non Small-cell Lung Cancer (NSCLC) SPI-1620, Docetaxel - Non Small Cell Lung Cancer (NSCLC) | Phase 2 | Terminated | Spectrum Pharmaceuticals, Inc | 34 | 2013-05-01 | 2021-10-13 |
| Phase II Study of SPI-1620 in Combination With Docetaxel as a Second-Line to Treat Biliary Cancer SPI-1620, Docetaxel - Biliary Cancer | Phase 2 | Terminated | Spectrum Pharmaceuticals, Inc | 30 | 2013-04-01 | 2021-10-13 |
Alzheimer Disease (1) · Biliary Tract Neoplasms (1) · Brain Ischemia (1) · Carcinoma, Non-Small-Cell Lung (1) · Dementia (1) · Stroke (1)
Pharmazz, Inc. (3) · Spectrum Pharmaceuticals, Inc (2)
India (3) · United States (2)
Anil Gulati (3)